Moderna Inc | The Business Standard
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
TUESDAY, MAY 24, 2022
TUESDAY, MAY 24, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা

Moderna Inc

Moderna has recently signed vaccine orders for 2022 worth $17 billion — which would make it one of the best-selling drugs in the world. Photo: Reuters
Coronavirus chronicle

Moderna raises full-year Covid vaccine sales forecast to $21 billion

Coronavirus: On 16 November, 2020, US biotech company Moderna announced a vaccine against Covid-19 that is 94.5% effective. Montreal, 16 November, 2020/ Reuters
Global Economy

Covid vaccine maker Moderna flags Japan ambition with sumo sponsorship

Moderna has recently signed vaccine orders for 2022 worth $17 billion — which would make it one of the best-selling drugs in the world. Photo: Reuters
Coronavirus chronicle

Moderna plots vaccines against 15 pathogens with future pandemic potential

Coronavirus: On 16 November, 2020, US biotech company Moderna announced a vaccine against Covid-19 that is 94.5% effective. Montreal, 16 November, 2020/ Reuters
Coronavirus chronicle

Moderna cuts 2021 sales forecast for Covid-19 vaccine; shares tumble

FILE PHOTO: A healthcare worker holds a vial of the Moderna COVID-19 vaccine at a pop-up vaccination site operated by SOMOS Community Care during the coronavirus disease (COVID-19) pandemic in Manhattan in New York City, New York, U.S., January 29, 2021. REUTERS/Mike Segar/File Photo
Coronavirus chronicle

US FDA clears Moderna, J&J Covid-19 boosters, backs use of different vaccine for boost

Pfizer, Moderna vaccines stop infections in real-world study
Coronavirus chronicle

Pfizer, Moderna vaccines stop infections in real-world study

Coronavirus: On 16 November, 2020, US biotech company Moderna announced a vaccine against Covid-19 that is 94.5% effective. Montreal, 16 November, 2020/ Reuters
Coronavirus chronicle

UK begins rollout of Moderna Covid vaccine in Wales

FILE PHOTO: Vials labelled "COVID-19 Coronavirus Vaccine" and a syringe are seen in front of the Pfizer logo in this illustration taken February 9, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
Coronavirus chronicle

Pfizer, Moderna Covid-19 vaccines highly effective after first shot in real-world use, US study shows

Photo: Collected
Coronavirus chronicle

Moderna begins study of Covid-19 vaccine in kids

The AstraZeneca logo is pictured outside the AstraZeneca office building in Brussels as part of the coronavirus disease (COVID-19) vaccination campaign, Belgium, January 28, 2021. REUTERS/Johanna Geron
Global Economy

AstraZeneca has sold its stake in Moderna for more than $1 billion: The Times

What J&J's authorized Covid-19 shot means for the US vaccination campaign
Analysis

What J&J's authorized Covid-19 shot means for the US vaccination campaign

FILE PHOTO: Vials with a sticker reading "Covid-19/Coronavirus vaccine/Injection only" and a syringe are seen in front of a displayed Moderna logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
Coronavirus chronicle

Moderna wants to pack 50pc more Covid vaccine per vial

Moderna Covid vaccines delayed in Europe and elsewhere, adding to shortfalls
Coronavirus chronicle

Moderna Covid vaccines delayed in Europe and elsewhere, adding to shortfalls

  • Show More
The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab